September 23, 2019

Craig Ellins
Chief Executive Officer
One World Pharma, Inc.
3471 West Oquendo Road, Suite 301
Las Vegas, NV 89118

       Re: One World Pharma, Inc.
           Registration Statement on Form S-1
           Filed September 12, 2019
           File No. 333-233735

Dear Mr. Ellins:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-1

Cover Page

1.     We note your disclosure that your common stock is currently quoted on
the OTC Pink.
       Please confirm your understanding that being quoted on the OTC Pink does
not satisfy the
       requirement that there be an established public trading market with
respect to secondary
       at-the-market offerings for purposes of identifying the offering price
on the prospectus
       cover page as required by Item 501(b)(3) of Regulation S-K. Please
revise to clarify that
       the selling shareholders will sell at a fixed price or within a bona
fide price range until
       your shares are listed or quoted on an established public trading market
and thereafter at
       prevailing market prices or privately negotiated prices.
 Craig Ellins
One World Pharma, Inc.
September 23, 2019
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Donald Field at 202-551-3680 or Justin Dobbie at
202-551-3469 with
any questions.



FirstName LastNameCraig Ellins                             Sincerely,
Comapany NameOne World Pharma, Inc.
                                                           Division of
Corporation Finance
September 23, 2019 Page 2                                  Office of Healthcare
& Insurance
FirstName LastName